Mepsevii (Vestronidase alfa-vjbk)

Mepsevii (Vestronidase alfa-vjbk)

Mepsevii

Vestronidase alfa-vjbk

Injection: 10 mg/5 mL (2 mg/mL) in a single-dose vial

Ultragenyx Pharmaceutical Inc.

Medical Use

Mepsevii is a recombinant human lysosomal beta glucuronidase used to treat both children and adults with mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.

Limitations of Use

The impact of Mepsevii on the central nervous system symptoms of MPS VII is not yet known.

Recommended Dosage: Mepsevii should be administered under the supervision of a healthcare professional who can manage anaphylaxis. Premedication is necessary 30-60 minutes before starting the infusion.

The recommended dose of Mepsevii is 4 mg per kg (4 mg/kg), given by intravenous infusion every two weeks.

The infusion should be administered over about 4 hours. During the first hour, infuse 2.5% of the total volume. After the first hour, the infusion rate can be increased to complete the remaining volume over the next 3 hours, as tolerated.